Literature DB >> 16103127

beta-amyloid is different in normal aging and in Alzheimer disease.

Alessandra Piccini1, Claudio Russo, Alessandra Gliozzi, Annalisa Relini, Antonella Vitali, Roberta Borghi, Luca Giliberto, Andrea Armirotti, Cristina D'Arrigo, Angela Bachi, Angela Cattaneo, Claudio Canale, Silvia Torrassa, Takaomi C Saido, William Markesbery, Pierluigi Gambetti, Massimo Tabaton.   

Abstract

The mechanism of neurodegeneration caused by beta-amyloid in Alzheimer disease is controversial. Neuronal toxicity is exerted mostly by various species of soluble beta-amyloid oligomers that differ in their N- and C-terminal domains. However, abundant accumulation of beta-amyloid also occurs in the brains of cognitively normal elderly people, in the absence of obvious neuronal dysfunction. We postulated that neuronal toxicity depends on the molecular composition, rather than the amount, of the soluble beta-amyloid oligomers. Here we show that soluble beta-amyloid aggregates that accumulate in Alzheimer disease are different from those of normal aging in regard to the composition as well as the aggregation and toxicity properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103127     DOI: 10.1074/jbc.M501694200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.

Authors:  Roxanna Perez-Garmendia; Vanessa Ibarra-Bracamontes; Vitaly Vasilevko; Jose Luna-Muñoz; Raul Mena; Tzipe Govezensky; Gonzalo Acero; Karen Manoutcharian; David H Cribbs; Goar Gevorkian
Journal:  J Neuroimmunol       Date:  2010-09-22       Impact factor: 3.478

2.  Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice.

Authors:  Götz Heilbronner; Yvonne S Eisele; Franziska Langer; Stephan A Kaeser; Renata Novotny; Amudha Nagarathinam; Andreas Aslund; Per Hammarström; K Peter R Nilsson; Mathias Jucker
Journal:  EMBO Rep       Date:  2013-09-03       Impact factor: 8.807

3.  Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.

Authors:  Christopher P Sullivan; Eric A Berg; Rosemary Elliott-Bryant; Jordan B Fishman; Ann C McKee; Peter J Morin; Michael A Shia; Richard E Fine
Journal:  Neurosci Lett       Date:  2011-10-06       Impact factor: 3.046

4.  Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.

Authors:  Erwin Cabrera; Paul Mathews; Emiliya Mezhericher; Thomas G Beach; Jingjing Deng; Thomas A Neubert; Agueda Rostagno; Jorge Ghiso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-13       Impact factor: 5.187

5.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

6.  Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.

Authors:  Krysti Todd; Silvia Fossati; Jorge Ghiso; Agueda Rostagno
Journal:  Biochim Biophys Acta       Date:  2014-09-28

7.  Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.

Authors:  Erik Portelius; Bin Zhang; Mikael K Gustavsson; Gunnar Brinkmalm; Ann Westman-Brinkmalm; Henrik Zetterberg; Virginia M-Y Lee; John Q Trojanowski; Kaj Blennow
Journal:  Neurodegener Dis       Date:  2009-12-03       Impact factor: 2.977

8.  Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.

Authors:  Markus Morawski; Maike Hartlage-Rübsamen; Carsten Jäger; Alexander Waniek; Stephan Schilling; Claudia Schwab; Patrick L McGeer; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2010-04-10       Impact factor: 17.088

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.